Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Task Force Calls for Consolidation in Vaccines, Blood Products Industries; “Fundamental to National Security”: Minister
October 20, 2016
- LDP Taskforce Agrees to Squeeze Social Security Budget by 140 Billion Yen
October 19, 2016
- Opdivo Ordered to Add Immune Thrombocytopenic Purpura in ADR List
October 19, 2016
- Concomitant Use of Warfarin and Florid Contraindicated: MHLW
October 19, 2016
- Health Minister Nudges Kaketsuken on Biz Handover to Astellas
October 19, 2016
- Urgent Need for Rule on Interim NHI Price Revisions; Current System Unable to Respond in Case of Add’l Indications: MOF Budget Examiner
October 19, 2016
- MHLW Panel to Review Ono’s Etelcalcetide on Oct. 31
October 18, 2016
- Govt to Stockpile Qinghai Strain Pre-Pandemic Flu Vaccines
October 18, 2016
- Govt Panel Member Pushes 50%-Plus Cut for Opdivo Price
October 17, 2016
- MHLW Panel to Discuss Opdivo for Hodgkin’s Lymphoma on Oct. 27
October 17, 2016
- Huge Costs, Amount of Application Data Required Will Be Major Challenges in Development of Biosimilars: Open Forum
October 14, 2016
- Health Minister to “Positively Consider” Setting Biosimilars Use Target
October 14, 2016
- AMED to Open Office in Washington D.C.
October 13, 2016
- 30% of Rejected Requests for Health Damage Compensation Due to Improper Drug Use: MHLW
October 12, 2016
- MHLW Study Group to Revise 75 Manuals on Serious ADRs in 19 Fields Over 5-Year Period
October 12, 2016
- MHLW to Consider Additional Penalties for Kaketsuken after Reviewing Its Report: Minister Shiozaki
October 11, 2016
- Current Information Disclosure for DPO Discussions Appropriate: Shiozaki
October 7, 2016
- Univ. of Tokyo and Kyoto Univ. Selected to Participate in Project to Train Biostatisticians: AMED
October 7, 2016
- Make “High-Level Investment” Credits Permanent under R&D Tax Break: Industry
October 6, 2016
- Chuikyo Green-Lights Basic Plans on “Optimal Use Guidelines,” Notification Letters
October 6, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…